Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Xie S, Zhou W, Tian L, Niu J, Liu Y
Midday administration (46 hours post 5-Amino-1MQ): MOTS-c 510mg subcutaneously
FOXO4-DRI vs nearby senolytics Option FOXO4-DRI Type D-retro-inverso peptide Human trial stage None (preclinical only) Option Dasatinib + Quercetin (D+Q) Type Small-molecule drug + flavonoid Human trial stage Early human trials (e.g., Alzheimer's) Option Navitoclax Type BCL-2 family inhibitor Human trial stage Later-stage trials (e.g., myelofibrosis) D+Q and navitoclax are further along in humans but can affect healthy cells (e.g., low platelets)
Among all tested concentrations, 0.1 mM Epitalon significantly reduced reactive oxygen species accumulation compared to untreated aged oocytes
These findings support the rationale for the multi-peptide approach embodied in KLOW Blend
For patients weighing MOTS-c vs Sermorelin, this lab work is essential it reveals whether your fatigue is driven by mitochondrial inefficiency, hormonal decline, cellular depletion, or some combination
US$ 28.09
US$ 27.24
US$ 22.38
US$ 22.78
